Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
This research aims to observe patients who participated in the EXCELLENT clinical trial for acute myocardial infarction. It focuses on comparing long-term clinical outcomes between those who received standard care and those treated with ProtheraCytes. The study is designed to follow these patients for up to 10 years to gather valuable safety and efficacy data. Participants include those from both the standard of care group and the ProtheraCytes treatment group who have completed their 6-month follow-up in the original EXCELLENT trial. This observational study involves collecting data without additional interventions or treatments. The study duration spans an average of 10 years from the initial randomization in the EXCELLENT trial. During the study, researchers will monitor participants regularly to assess safety and treatment outcomes over the long term. Data collection includes clinical evaluations and tracking of any health changes. The study does not involve new treatments but focuses on observing and comparing patient progress. Participants will continue their usual care outside the study, and their safety will be monitored throughout.
Actively Recruiting
The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of radiofrequency RF ablation for type-I atrial flutter. This study specifically examines the use of the Vision-MR Ablation Catheter 2.0 within an interventional cardiac magnetic resonance iCMR environment to treat this heart rhythm disorder. Participants receive RF ablation treatment for type I atrial flutter using the Vision-MR Ablation Catheter 2.0 along with the Advantage-MR EP recorder and stimulator system while under iCMR guidance. The study actively monitors the procedures success and safety during and shortly after treatment, focusing on achieving a bi-directional conduction block and observing serious cardiovascular events. Throughout the trial, participants undergo assessments to confirm the treatments effectiveness immediately after the procedure and at 90 days post-treatment. Researchers measure the primary efficacy endpoint by confirming the conduction block during the procedure and monitor safety by tracking serious cardiovascular adverse events for seven days after. Secondary measures include freedom from atrial flutter recurrence and serious adverse events over three months. The study aims to complete participant follow-up by the end of 2026.
Actively Recruiting
Researchers are evaluating the Colibri Transcatheter Aortic Heart Valve System in patients aged over 75 years who have symptomatic severe aortic stenosis and are at high surgical risk. This prospective, single-arm clinical investigation will be conducted at about seven European sites to assess the safety and performance of this heart valve system compared to recent historical results. The primary focus is on the rate of all-cause mortality at 30 days post-implantation, with additional evaluations up to five years after the procedure. Participants will receive the Colibri heart valve implanted via transfemoral access. This treatment is intended for patients with severe aortic tricuspid valve stenosis who meet specific anatomical and clinical criteria, such as heart valve measurements and surgical risk assessments. The study involves a single treatment group receiving the investigational device, with follow-up visits scheduled at 30 days, 6 months, 12 months, and annually up to five years to monitor the devices performance and safety. During the study, participants will undergo assessments including ECG-gated Multi-Slice Computed Tomography MSCT for valve measurements and clinical evaluations by the Heart Team and a Centralized Case Review Committee. Researchers will track mortality and adverse events, along with heart function and symptom status. Participants are expected to provide informed consent and agree to scheduled follow-ups to help researchers understand the devices long-term impact on patient health and safety.
Actively Recruiting
The trial investigates the use of various early brain damage scoring systems in adult patients admitted to intensive care units after experiencing cardiac arrest. Cardiac arrest patients often face poor outcomes despite successful return of spontaneous circulation, and doctors use several scores to predict prognosis and guide post-resuscitation care. This study aims to compare and externally validate these scoring methods to identify the most effective tool for treatment decisions and communication with patient relatives. Participants will have early prognosis scores calculated at intensive care unit admission, typically within about three hours after the cardiac arrest event. These scores are based on clinical and biological values and are assessed without altering standard care, as this is an observational study focused on diagnostic evaluation. The study does not involve experimental treatments but observes and compares existing scoring methods. During the study, participants will be monitored through their intensive care admission, where data relevant to the scoring systems will be collected. Researchers will measure the accuracy of the Cerebral Admission Hospital Prognosis CAHP Score and other scores by determining their predictive value for patient outcomes. The study spans several years, with the primary outcome measured at ICU admission and the overall study completion expected by the end of 2027.
Actively Recruiting
Researchers are evaluating a new method to record the hearts electrical activity using a high-density electrocardiogram HD ECG with 128 electrodes placed on the body surface. This method aims to capture more detailed cardiac signals compared to the conventional 12-lead ECG, which measures electrical activity from fewer locations and may miss signals from certain areas. The study focuses on patients with ventricular arrhythmias or related heart conditions to see if HD ECG provides additional clinical information. The study involves two types of ECG recordings done simultaneously the standard 12-lead ECG and the experimental HD ECG device. The HD ECG uses 128 skin electrodes arranged in strips, prepared with adhesive tape and conductive gel, recording for 10 to 30 minutes. The conventional 12-lead ECG is derived from specific electrodes within the HD ECG setup, plus four limb electrodes for frontal leads. Participants include those with documented or suspected severe ventricular arrhythmias or those undergoing preventive ventricular defibrillator implantation. Participants will undergo both ECG recordings on the same day, during which researchers will identify electrical criteria such as amplitude, timing, duration, and anatomical locations of cardiac activity using the HD ECG. The study measures these outcomes to assess the sensitivity of the HD ECG method. The trial is non-blinded and conducted at Bordeaux University Hospital, with patient safety monitored throughout the recording process. The total participation involves one study visit for the ECG assessments.
Actively Recruiting
This observational study evaluates the Polymer Free Sirolimus Eluting Coronary Stent System, known as the Vivo ISAR, in everyday clinical practice for patients with coronary artery stenosis. The purpose is to collect real-world data on clinical outcomes over a 12-month follow-up period, focusing on patients who receive this stent system as part of their routine care. The study is sponsored by Translumina GmbH and involves standard procedures and medications with known safety profiles. Participants will be treated with the Vivo ISAR stent during percutaneous coronary intervention to improve coronary artery diameter in those experiencing symptoms of ischemic heart disease. The study monitors patients who receive the stent in one or multiple vessels, observing their progress without altering standard care practices. The follow-up extends to 12 months after the procedure to assess various success rates and treatment effects. During the study, participants undergo routine clinical evaluations including assessments of device and procedural success shortly after treatment, and measures of target lesion failure and reperfusion at 12 months. Researchers also evaluate antiplatelet therapy adherence and effectiveness. The total participation involves regular check-ups and data collection to understand long-term outcomes and safety of the Vivo ISAR stent system in typical healthcare settings.
Actively Recruiting
Researchers are evaluating the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients who have moderate to severe mitral regurgitation and are considered high risk for traditional open-heart surgery. This study focuses on patients with significant mitral valve leakage and who have specific heart failure symptoms classified as New York Heart Association NYHA Class II, III, or ambulatory IV. The study is sponsored by HighLife SAS and aims to gather information on this device in a real-world setting without randomization. Participants will receive the HighLife Transcatheter Mitral Valve Replacement device through a trans-septal catheter procedure. This is a single-arm, non-randomized study where all participants undergo this intervention. The study will monitor the devices safety primarily within the first 30 days after implantation. The procedure is designed for patients who meet specific anatomical criteria and have been on guideline-directed medical therapy for at least one month. Throughout the study, participants will be closely followed with scheduled assessments to evaluate the devices safety and overall performance. Researchers will monitor for adverse events and clinical outcomes, focusing on the 30-day safety period after treatment. The study includes follow-up visits and evaluations to ensure participant well-being and to gather comprehensive data on the devices effects. Participation lasts according to the study protocol, with ongoing monitoring as needed.
Actively Recruiting
Researchers are evaluating the use of arginine-vasopressin AVP and hydrocortisone compared with norepinephrine to improve survival and neurological recovery 30 days after cardiac arrest in patients experiencing hemodynamic failure. This phase 3, multicenter trial focuses on patients who have been successfully resuscitated but face post-resuscitation syndrome, which includes multiple organ failures and brain damage caused by a combination of heart and circulatory problems often linked to hormonal imbalances. The study randomly assigns participants to one of four groups AVP with placebo hydrocortisone, placebo AVP with hydrocortisone, both AVP and hydrocortisone, or placebo for both. AVP is given via infusion to maintain a target blood pressure for up to 3 days, while hydrocortisone is administered intravenously every 6 hours for 7 days without tapering at the end. Placebo treatments are used to compare effects. The trial involves 17 intensive care units in France and aims to enroll 380 patients. Participants will be closely monitored throughout the study with assessments including neurological outcome measured at day 30, along with various mortality causes and brain damage evaluations at 48 and 72 hours. Researchers will track survival, brain function recovery, and hemodynamic stability during and after treatment. The study uses quadruple masking to ensure unbiased results and includes ongoing safety and follow-up evaluations until December 2025.
Actively Recruiting
Researchers are evaluating the impact of adding three sensory elementsvisual, auditory, and olfactoryto help reduce discomfort in adult patients hospitalized in intensive care or continuing care units. This study includes patients admitted for medical or surgical reasons, whether conscious or unconscious and under mechanical ventilation. The goal is to explore supportive care methods to improve patient comfort during hospital stays. Participants are randomly assigned to either an experimental group that experiences an immersive sensory environment in their hospital room or a control group that receives standard care without sensory projections. The sensory environment includes light frescoes themed on nature with a circadian cycle, immersive nature sounds that are non-repetitive, and the use of essential oils. All patients continue to receive usual medical care and support from the hospital team. Throughout the study, patients and their relatives will be monitored and supported as per usual intensive care practices. Researchers will assess patient discomfort using the REAnimation Patient Discomfort Questionnaire over a two-month period. The study involves informed consent from patients or their trusted persons who understand French and the research procedures. The total participation timeline aligns with the hospitalization duration and follow-up for assessing discomfort.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Myval Transcatheter Heart Valve THV Series compared to Contemporary Valves, including the Sapien THV Series and Evolut THV Series, in patients with severe symptomatic native aortic valve stenosis. This multinational, prospective, randomized trial involves 768 participants and aims to assess whether the Myval device performs at least as well as the other commercially available valves in improving heart valve function. Participants will be randomly assigned to receive either the Myval THV Series or one of the Contemporary Valves via a transfemoral approach. The Myval devices come in various sizes ranging from 20 mm to 29 mm, with additional registries for extra-large sizes. Separate study groups include a non-randomized nested registry for extra-large Myval devices and a lead-in set to ensure procedural adherence by investigators before enrolling subjects. During the study, participants will undergo assessments including clinical evaluations and imaging to monitor valve function and safety over time. Outcomes measured include a combined safety and effectiveness endpoint at 30 days, as well as longer-term monitoring for mortality, stroke, kidney injury, valve performance, and quality of life up to 10 years. The study involves follow-ups at multiple timepoints to comprehensively evaluate the devices performance and patient health.
1-10 of 23
1